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Baseline absolute risk estimation 
 
The baseline risk of myocardial infarctions and strokes was estimated using the WHO-
ISH equations calibrated to the South African population in the case of the WHO PEN guidelines 
[1], with twice the baseline risk of recurrence for those with a prior history of myocardial 
infarction or stroke [2]. The baseline risk over a 10-year period is provided in Appendix Table 
1. Risk estimates for individuals (with inputs of age, sex, tobacco smoking status, systolic blood 
pressure, diabetes status, and total cholesterol), can be obtained using the whoishRisk package in 
R [1]. For the SA PC 101 guideline, the alternative Harvard/NHANES risk calculations are 
recommended and were therefore applied instead [33]. Risk estimates were linearly imputed for 
ages <40 years old.  
The baseline risk of all other outcomes (congestive heart failure exacerbations; renal 
failure/end-stage renal disease (ESRD) due to hypertensive or diabetic nephropathy; severe 
vision loss attributable to diabetic retinopathy; and pressure sensation loss or further severe 
diabetic neuropathy) was based on the RECODe equations [3,4] calibrated to the South African 
population by adjusting the baseline event rate parameter to produce the reported annual total 
population DALY estimate for each outcome from the Global Burden of Disease project in the 
base case scenario [5]. The equations are provided in Appendix Table 2. Risk estimates for 
individuals (with inputs of age, sex, race/ethnicity, tobacco smoking status, systolic blood 
pressure, cardiovascular disease history, medication treatment with blood pressure agents, 
treatment with statins, treatment with anticoagulant drugs, hemoglobin A1c, total and high-
density lipoprotein cholesterol, serum creatinine, and urine microalbumin/creatinine ratio), can 
be obtained using an online calculator and associated open source code in R [6,7]. 
Case fatality rates following events and all-cause mortality was obtained by age and sex 
from projections over the simulated time period from the South Africa National Burden of 
Disease Study [8].   
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Relative risk reduction equations 
With blood pressure treatment, the relative risk reduction for atherosclerotic 
cardiovascular disease events was estimated using the Smith-Spangler equation calculating 
relative risk (RR) as a function of age (in years) and change in systolic blood pressure (∆SBP) 
[9]: 
𝑅𝑅𝑅𝑅 = 2∆𝑆𝑆𝑆𝑆𝑆𝑆(−0.0000184775×𝑎𝑎𝑎𝑎𝑎𝑎2+0.001584×𝑎𝑎𝑎𝑎𝑎𝑎+0.028672) 
where the change in systolic blood pressure by medication class and dosage was obtained from a 
meta-analysis of 354 randomized trials (Appendix Table 3) [10]. 
With angiotensin-converting-enzyme inhibitor therapy, the relative risk reduction in for 
congestive heart failure exacerbations was estimated as 22% (95% CI: 6%, 35%) [11]. With 
blood pressure treatment, the relative risk for renal failure conditional on baseline systolic blood 
pressure (SBP) and reduction in systolic blood pressure (∆SBP) was estimated as [12]: 
𝑅𝑅𝑅𝑅 = �𝑆𝑆𝑆𝑆𝑆𝑆 − ∆𝑆𝑆𝑆𝑆𝑆𝑆
𝑆𝑆𝑆𝑆𝑆𝑆
�
2.5640
 
and the relative risk for retinopathy among those with diabetes was estimated as [12]: 
𝑅𝑅𝑅𝑅 = �𝑆𝑆𝑆𝑆𝑆𝑆 − ∆𝑆𝑆𝑆𝑆𝑆𝑆
𝑆𝑆𝑆𝑆𝑆𝑆
�
6.4249
 
 With dyslipidemia treatment, the relative risk reduction for myocardial infarction and 
stroke from statin treatment was estimated as 21% (95% CI: 19%, 23%) [13].  
With glycemic treatment of type 2 diabetes, the relative risk for nephropathy conditional 
on baseline hemoglobin A1c (A1c) and reduction in systolic blood pressure (∆A1c) was 
estimated as [12]: 
𝑅𝑅𝑅𝑅 = �𝐴𝐴1𝑐𝑐 − ∆𝐴𝐴1𝑐𝑐
𝐴𝐴1𝑐𝑐 �1.1025 
while the relative risk for neuropathy was estimated as [12]: 
𝑅𝑅𝑅𝑅 = �𝐴𝐴1𝑐𝑐 − ∆𝐴𝐴1𝑐𝑐
𝐴𝐴1𝑐𝑐 �1.4325 
and the relative risk for retinopathy as [12]: 
𝑅𝑅𝑅𝑅 = �𝐴𝐴1𝑐𝑐 − ∆𝐴𝐴1𝑐𝑐
𝐴𝐴1𝑐𝑐 �2.5144 
The reduction in baseline hemoglobin A1c by medication class and dosage was obtained from a 
review of treatment agents (Appendix Table 4) [14]. 
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 DALY and cost calculations 
 An impact inventory specifying each set of costs and their sources is provided in 
Appendix Table 5, while DALY disutility estimates for each outcome are provided in 
Appendix Table 6. The CHEERS guideline checklist for cost-effectiveness analysis reporting 
[15] is provided in Appendix Table 7.  
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Appendix Table 1. WHO-ISH risk estimates for 10-year risk of atherosclerotic cardiovascular 
disease events [1]. Of total events, 57% in South Africa are myocardial infarctions, and the rest 
strokes [5].  
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 Appendix Table 2.  RECODe equations [3,4]. The 10-year risk of an outcome can be computed 
as 1 – λ^exp(Σ(β×x) – mean(Σ(β×x))), where β are the equation coefficients and x are the values 
for each covariate for an individual patient within the cohort under study. λ values are: 0.973 for 
renal failure, 0.921 for vision loss, 0.870 for pressure sensation loss, and 0.960 for heart failure, 
and corresponding values of mean(Σ(β×x)) are 0.23 for renal failure, 4.56 for vision loss, 4.75 
for pressure sensation loss, and 5.15 for heart failure. 
 
 Renal failure/end-stage 
renal disease  
Severe vision 
loss  
Pressure 
sensation loss  
Heart 
failure  
Demographics     
     
Age, years      
 -0.019380 0.022850 0.03022 0.052680 
Women      
 -0.011290 0.226400 -0.18680 0.252900 
Ethnicity      
     
Black      
 -0.088120 -0.167700 -0.09448 -0.049690 
Clinical features     
     
Tobacco smoking, current      
 0.148300   0.290500 
Systolic blood pressure, mm Hg      
 0.003027 0.008243 0.00456 0.001217 
Cardiovascular disease history      
 -0.021640 0.112700 0.26672 1.007000 
Drug use     
     
Blood pressure- lowering drugs      
 -0.079520 0.063930 0.18192 0.638900 
Oral diabetes drugs      
 -0.125600 -0.234900 -0.25747 -0.117500 
Anticoagulants      
 0.031990   0.736500 
 
Biomarkers     
     
HbA1c, %      
 0.136900 0.144900 0.18866 0.209200 
Total cholesterol, mg/dL     
 -0.001112 -0.000168 0.00219 -0.001358 
HDL cholesterol, mg/dL     
 0.006289 0.005447 -0.00539 -0.017580 
Serum creatinine, mg/dL     
 0.860900 0.694700 0.60442 0.821400 
Urine albumin:creatinine ratio, mg/g      
 0.000362 0.000199  0.000414 
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Appendix Table 3: Blood pressure reductions achieved through treatment agents [10]. 
 
Treatment agent  Reduction in systolic blood pressure at standard dose* 
(mmHg, 95% CI) 
Angiotensin converting enzyme (ACE) inhibitor 8.5 (7.9, 9.0) 
Beta-blocker 9.2 (8.6, 9.9) 
Thiazide diuretic 8.8 (8.3, 9.4) 
Calcium channel blocker 8.8 (8.3, 9.2) 
*standard doses were 10mg for Lisinopril (ACE inhibitor), 50mg for atenolol (beta-blocker), 2.5mg for 
bendroflumethazide (thiazide), and 5mg for amlodipine (calcium channel blocker).  
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Appendix Table 4: Hemoglobin A1c reductions achieved through treatment agents [14]. 
 
Treatment agent  Reduction in hemoglobin A1c (%, 95% CI) 
Metformin 850mg three times daily -1.3% (-1.0%, -1.5%) 
Sulfonylurea Glibenclamide 7.5mg twice daily -1.5% (-1.0%, -2.0%) 
Insulin, basal Unlimited, typical dose 0.5 IU/kg body weight 
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Appendix Table 5: Costs organized into an impact inventory [16]. Costs were constructed for 
treatment of each risk factor or outcome – as recommended by either SA PACK, WHO PEN, or 
other locally supported guidelines [17–22]– by breaking down each care-episode into its 
component parts and extracting costs for these from the South African Uniform Patient Fee 
schedule for 2012 (the year of SANHANES) [23]. Costs for blood tests were extracted from the 
National Health Laboratory Service fees for 2013 (as 2012 data were not available). Where there 
were no specific South African guidelines, we used clinical experience to inform care-
components for each treatment episode. Where there were two or more cost-options for the 
treatment components of a given risk factor or outcome, we chose the most conservative one 
(e.g., choosing a level two over the more expensive level three hospital care for procedures that 
could be done at either locale). Additionally, for treatment of an acute myocardial infarction, 
streptokinase was chosen over percutaneous coronary intervention due to cost and our clinical 
experience witnessing typical care across South Africa. Costs are expressed in 2018 U.S. Dollars 
based on the March 2018 exchange rate and consumer price index, and both costs and DALYs 
were discounted at a standard 3% annual rate. Note that the healthcare sector perspective was 
used throughout, with no societal reference case analysis given the absence of data concerning 
non-healthcare sectors.  
 
Cost category Cost subset Estimated 
cost impact 
($US) 
Hypertension Annual physician visit* 20/yr 
 Nurse visit every three months 37/yr 
 Annual electrolytes and urea labs 9/yr 
 Thiazide 52/yr 
 ACE inhibitor 69/yr 
 Calcium channel blocker 34/yr 
 Beta-blocker 1/yr 
Dyslipidemia Lipid labs 6 (once) 
 Annual physician visit 20/yr 
 Statin 34/yr 
Type 2 diabetes 
mellitus 
Annual physician visit 20/yr 
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 Nurse visit every three months 37/yr 
 Hemoglobin A1c every 6 months 13/yr 
 Lipid labs 6 (once) 
 Annual electrolytes and urea labs 9/yr 
 Metformin 62/yr 
 Sulfonylurea 204/yr 
 Insulin, basal 115/yr 
 Aspirin 1/yr 
 Statin 34/yr 
 ACE inhibitor 38/yr 
Atherosclerotic 
cardiovascular 
disease 
Myocardial infarction – acute care including transport, morphine, aspirin, 
prochlorperazine, streptokinase, 2-3 day hospital stay, enoxaparin, 
clopidogrel, echocardiography, daily electrolytes and urea, blood count, 
blood glucose, liver function testing, lipids, and thyroid function tests 
1,089 (once) 
 Myocardial infarction – monthly nurse visits x 6 months 55/yr 
 Myocardial infarction – annual physician follow-up 20/yr 
 Myocardial infarction – aspirin 1/yr 
 Myocardial infarction – beta-blocker 36/yr 
 Myocardial infarction – statin 34yr 
 Myocardial infarction – ACE inhibitor 125/yr 
 Myocardial infarction – electrolytes and urea every 6 months 17/yr 
 Stroke – acute care including transport, CT scan, aspirin, streptokinase, 14 
day hospital stay, electrolytes and urea, blood count, lipid labs, 
physiotherapy and occupational therapy for 5 days  
2,202 (once) 
 Stroke – monthly nurse visits x 6 months 55/yr 
 Stroke – annual physician follow-up 20/yr 
 Stroke – aspirin 1/yr 
 Stroke – statin 34/yr 
Congestive heart 
failure 
Acute exacerbation – including transport, morphine, isosorbide dinitrite, 
prochlorperazine, furosemide IV, low molecular-weight heparin, 5 day 
hospital stay, chest X-ray, echocardiography, electrolytes and urea, liver 
function testing, blood count, lipid labs, and thyroid function tests 
2,326 (once) 
 Monthly nurse visits x 6 months 55/yr 
 Annual physician follow-up 20/yr 
 Annual echocardiogram 145/yr 
 Diuretic 61/yr 
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 Beta-blocker 33/yr 
 Spironolactone 9/yr 
 Electrolytes and urea every 6 months 9/yr 
Renal failure/end-
stage renal disease 
A/V fistula surgery 466 (once) 
 Hemodialysis 3 sessions per week 16,052/yr 
 Physician visit every 3 months 81/yr 
 Electrolytes and urea tests every 3 months 35/yr 
 Parathyroid hormone every 3 months 55/yr 
 Blood count every 3 months 26/yr 
 Liver function tests every 3 months 53/yr 
 Calcium, alkaline phosphatase and albumin tests every 3 months 52/yr 
Diabetic retinopathy Annual ophthalmologist visit 20/yr 
 Opthalmology care every 6 months 40/yr 
Diabetic neuropathy Twice annual physician visit 40/yr 
 Twice annual nurse practitioner foot care follow-up 20/yr 
 Amytryptylline 17/yr 
 Acute ulcer (13% of those with neuropathy) – including 1 week 
hospitalization, wound care, blood count, electrolytes and urea, fasting 
glucose 
524 (once) 
 Acute ulcer follow-up care 59/yr 
 Minor amputation (0.4% of those with neuropathy) – including 1 week 
hospitalization, surgical theater time, anesthetist, surgeon, follow-up, blood 
count, electrolytes and urea, fasting glucose 
1,816 (once) 
 Minor amputation follow-up care 59/yr 
 Major amputation (0.4% of those with neuropathy) – including 2 weeks 
hospitalization, high dependency care, surgical theater time, anesthetist, 
surgeon, follow-up, prosthesis, blood count, electrolytes and urea, fasting 
glucose, physiotherapy 
3,706 (once) 
 Major amputation follow-up care 520/yr 
*the cost of annual physician visits, nurse visits, other services, and overlapping laboratory tests or medications were 
only counted once for patients with multiple concurrent risk factors or conditions, e.g., a single annual physician 
visit would be counted for a patient visiting the physician annually for both hypertension and diabetes. 
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Appendix Table 6: Disutilities used to computed disability-adjusted life-years, which were 
elicited through international standardized preference elicitation surveys [24]. Costs are 
expressed in 2018 U.S. Dollars, and both costs and DALYs were discounted at a standard 3% 
annual rate. The method of calculating DALYs from disutilities is specified in [25]. 
 
Disease event Estimated disutility on scale of 0 to 1 (95% CI) 
Atherosclerotic cardiovascular disease 0.28 (0.06, 0.57) 
Congestive heart failure 0.10 (0.04, 0.19) 
Renal failure/end-stage renal disease 0.34 (0.11, 0.57) 
Retinopathy 0.20 (0.10, 0.40) 
Neuropathy 0.10 (0.05, 0.20) 
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Appendix Table 7: CHEERS checklist [15]. 
 
Section Item No Recommendation Reported 
on  
Title and Abstract 
Title 1 Identify the study as an economic evaluation or use more 
specific terms such as “cost-effectiveness analysis”, and 
describe the interventions compared. 
Title 
Abstract 2 Provide a structured summary of objectives, perspective, 
setting, methods (including study design and inputs), results 
(including base case and uncertainty analyses), and 
conclusions. 
Abstract 
Introduction 
Background and 
objectives 
3 Provide an explicit statement of the broader context for the 
study. 
Present the study question and its relevance for health policy or 
practice decisions. 
Intro 
paragraphs 
1-3 
Methods 
Target population and 
subgroups 
4 Describe characteristics of the base case population and 
subgroups analysed, including why they were chosen. 
Methods 
section 1 
Setting and location 5 State relevant aspects of the system(s) in which the decision(s) 
need(s) to be made. 
Methods 
section 1 
Study perspective 6 Describe the perspective of the study and relate this to the 
costs being evaluated. 
Methods 
section 5 
Comparators 7 Describe the interventions or strategies being compared and 
state why they were chosen. 
Figure 1 
Time horizon 8 State the time horizon(s) over which costs and consequences 
are being evaluated and say why appropriate. 
Methods 
section 1 
Discount rate 9 Report the choice of discount rate(s) used for costs and 
outcomes and say why appropriate. 
Methods 
section 5 
Choice of health 
outcomes 
10 Describe what outcomes were used as the measure(s) of 
benefit in the evaluation and their relevance for the type of 
analysis performed. 
Methods 
section 3 
and 5 
Measurement of 
effectiveness 
11a Single study-based estimates: Describe fully the design 
features of the single effectiveness study and why the single 
study was a sufficient source of clinical effectiveness data. 
N/A 
 11b Synthesis-based estimates: Describe fully the methods used for 
identification of included studies and synthesis of clinical 
effectiveness data. 
Methods 
section 4 
Measurement and 
valuation of preference 
based outcomes 
12 If applicable, describe the population and methods used to 
elicit preferences for outcomes. 
Appendix 
Table 6 
Estimating resources 
and costs 
13a Single study-based economic evaluation: Describe approaches 
used to estimate resource use associated with the alternative 
interventions. Describe primary or secondary research methods 
N/A 
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for valuing each resource item in terms of its unit cost. 
Describe any adjustments made to approximate to opportunity 
costs. 
 13b Model-based economic evaluation: Describe approaches and 
data sources used to estimate resource use associated with 
model health states. Describe primary or secondary research 
methods for valuing each resource item in terms of its unit 
cost. Describe any adjustments made to approximate to 
opportunity costs. 
Appendix 
Table 5 
Currency, price date, 
and conversion 
14 Report the dates of the estimated resource quantities and unit 
costs. Describe methods for adjusting estimated unit costs to 
the year of reported costs if necessary. Describe methods for 
converting costs into a common currency base and the 
exchange rate. 
Appendix 
Table 5 
Choice of model 15 Describe and give reasons for the specific type of decision-
analytical model used. Providing a figure to show model 
structure is strongly recommended. 
Methods 
section 1 
Assumptions 16 Describe all structural or other assumptions underpinning the 
decision-analytical model. 
Methods 
sections 1 
and 2 
Analytical methods 17 Describe all analytical methods supporting the evaluation. This 
could include methods for dealing with skewed, missing, or 
censored data; extrapolation methods; methods for pooling 
data; approaches to validate or make adjustments (such as half 
cycle corrections) to a model; and methods for handling 
population heterogeneity and uncertainty. 
Methods 
sections 1, 
4 and 5 
Results 
Study parameters 18 Report the values, ranges, references, and, if used, probability 
distributions for all parameters. Report reasons or sources for 
distributions used to represent uncertainty where appropriate. 
Providing a table to show the input values is strongly 
recommended. 
Appendix 
tables 1-6 
Incremental costs and 
outcomes 
19 For each intervention, report mean values for the main 
categories of estimated costs and outcomes of interest, as well 
as mean differences between the comparator groups. If 
applicable, report incremental cost-effectiveness ratios. 
Table 2, 
Figure 2, 
Results 
sections 2-
4 
 
Characterizing 
uncertainty 
20a Single study-based economic evaluation: Describe the effects 
of sampling uncertainty for the estimated incremental cost and 
incremental effectiveness parameters, together with the impact 
of methodological assumptions (such as discount rate, study 
perspective). 
N/A 
 20b Model-based economic evaluation: Describe the effects on the 
results of uncertainty for all input parameters, and uncertainty 
related to the structure of the model and assumptions. 
Table 2, 
Results 
sections 2-
4 
Characterizing 
heterogeneity 
21 If applicable, report differences in costs, outcomes, or cost-
effectiveness that can be explained by variations between 
Figure 2 
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subgroups of patients with different baseline characteristics or 
other observed variability in effects that are not reducible by 
more information. 
Discussion 
Study findings, 
limitations, 
generalizability, and 
current knowledge 
22 Summarise key study findings and describe how they support 
the conclusions reached. Discuss limitations and the 
generalisability of the findings and how the findings fit with 
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Appendix Table 8. Distribution of outcome risk by age quintiles.  Given current levels of 
treatment estimated through the SANHANES survey, the WHO-ISH risk equations suggested a 
risk of atherosclerotic cardiovascular disease events or deaths averaging 9.9% over 10 years 
among the simulated population (95% CI: 0%, 56.0%), with 30% of the population having a risk 
>10% (mean age 62 years old, 95% CI: 42, 85), 19% with risk >20% (mean age 66 years old, 
95% CI: 46, 86), and 11% with risk >30% (mean age 68 years old, 95% CI: 50, 86). The 
RECODe risk equations suggested the risk of congestive heart failure was 1.8% over 10 years 
(95% CI: 0%, 11.2%), risk of renal failure/ESRD was 0.8% over 10 years (95% CI: 0%, 8.1%) in 
the general population and 6.2% over 10 years among those with diabetes (95% CI: 2.9%, 
12.8%), risk of severe vision loss from diabetic retinopathy was 7.1% over 10 years among those 
with diabetes (95% CI: 2.9%, 12.8%), and risk of pressure sensation loss or further severe 
diabetic neuropathy was 10.1% over 10 years among those with diabetes (95% CI: 2.1%, 25.0).  
 
 
Age quintile 
(N in 
SANHANES 
survey) 
Risk of 
atherosclerotic 
cardiovascular 
disease 
(myocardial 
infarction or 
stroke, % over 
10 years, 95% 
CI) 
Risk of 
congestive 
heart failure 
(% over 10 
years, 95% CI) 
Risk of renal 
failure/ESRD 
(% over 10 
years, 95% CI) 
Risk of severe 
vision loss from 
diabetic 
retinopathy (% 
over 10 years, 
95% CI) 
Risk of 
pressure 
sensation or 
further severe 
diabetic 
neuropathy (% 
over 10 years, 
95% CI) 
<22 years old 
(3,644) 
0 (0, 0) 0.2 (0.1, 0.4) 0.1 (0, 0.1) 0 (0, 0) 0 (0, 0) 
22-<33 years 
old 
(4,374) 
0.2 (0, 2.2) 0.3 (0.1, 0.9) 0.3 (0, 8.4) 0.1 (0, 2.2) 0.1 (0, 2.2) 
33-<46 years 
old 
(3,664) 
3.7 (0, 21.0) 0.8 (0.3, 3.0) 0.7 (0, 8.6) 0.4 (0, 4.8) 0.5 (0, 5.1) 
46-59 years old 
(3,241) 
13.9 (2.0, 47.9) 2.0 (0.5, 8.5) 1.4 (0, 8.8) 1.3 (0, 8.9) 1.9 (0, 13.6) 
>59 years old 
(2,709) 
33.2 (7.4, 91.3) 5.4 (1.0, 18.1) 1.5 (0, 7.1) 2.9 (0, 13.1) 4.2 (0, 22.7) 
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Appendix Table 9. Disability-adjusted life-years (DALYs), costs, and incremental cost-
effectiveness of treating elevated blood pressure, dyslipidemia, and type 2 diabetes mellitus for 
the South African population, based on current treatment levels (base case), versus with scale-up 
from currently-observed levels of treatment to 60% population access per the World Health 
Organization’s Package of Essential Non-communicable disease interventions (WHO PEN), or 
per the South Africa’s Primary Care 101 Guidelines (SA PC 101).20,21 95% confidence intervals 
in parentheses are calculated by re-running the model 10,000 times while repeatedly Monte 
Carlo sampling with replacement from the distributions of all input parameters to estimate 
uncertainty in the outcome metrics. Compare to main text Table 2. We found that at least 46.7% 
of the population would need to be diagnosed and treated for hypertension and hyperlipidemia to 
achieve the 30% mortality reduction goal, which would not require new blood pressure or lipid 
screening but would require more treatment initiation and adherence. 
 
Outcome metric, 
mean (95% CI) 
Treatment condition 
Base case (current 
levels of treatment) 
WHO PEN 
guidelines 
implemented 
SA PC 101 
guidelines 
implemented 
Disability-adjusted life-years lost, per 1,000 population per year 
All simulated 
outcomes 
40.0 (29.5, 52.0) 33.4 (22.5, 45.0) 33.0 (22.5, 45.0) 
 
Atherosclerotic 
cardiovascular 
disease 
18.7 (15.8, 21.8) 14.0 (11.1, 17.1) 13.6 (10.7, 16.7) 
Congestive heart 
failure 
10.7 (7.3, 14.6) 9.9 (6.5, 13.8) 9.8 (6.4, 13.7) 
Renal failure/end-
stage renal disease 
9.2 (5.5, 13.5) 8.3 (4.6, 12.6) 8.4 (4.7, 12.7) 
Diabetic retinopathy 0.8 (0.5, 1.3) 0.6 (0.3, 1.1) 0.6 (0.1, 1.1) 
Diabetic neuropathy 0.6 (0.4, 0.8) 0.6 (0.4, 0.8) 0.6 (0.4, 0.8) 
Healthcare costs, $ per 1,000 population per year 
All simulated risk 
factors and outcomes 
607,820 (513,818, 
705,805) 
472,889 (283,132, 
676909) 
419,939 (254,052, 
596,355) 
Hypertension 26,429 (26,326, 
26,533) 
23,159 (19,764, 
26,677) 
33,557 (28,920, 
37,809) 
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Dyslipidemia 6,585 (6,308, 6,860) 9,712 (8,847, 10,545) 9,847 (8,968, 10,751) 
Type 2 diabetes 
mellitus 
183,006 (170,185, 
195,023) 
120,592 (66,909, 
167,877) 
67,822 (48,004, 
87,393) 
Atherosclerotic 
cardiovascular 
disease 
248,108 (226,170, 
270,567) 
195,751 (157,355, 
230,503) 
194,545 (153,101, 
229,652) 
Congestive heart 
failure 
29,243 (21,778, 
37,251) 
24,525 (12,556, 
38,865) 
24,439 (12,556, 
39,463) 
Renal failure/end-
stage renal disease 
138,195 (87,520, 
192,544) 
119,951 (36,524, 
225,223) 
120,908 (30,437, 
225,223) 
Diabetic retinopathy 587 (371, 808) 448 (137, 843) 458 (182, 820) 
Diabetic neuropathy 2,096 (1,486, 2,752) 1,910 (804, 3,043) 1,910 (804, 3,043) 
Incremental cost-
effectiveness ratio 
(Change in $/change 
in DALYs), versus 
base case 
- -$20,313 (-$34,729, -
$4,350) 
-$26,671 (-$36,874, -
$15,537) 
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Appendix Table 10. Disability-adjusted life-years (DALYs), costs, and incremental cost-
effectiveness of treating elevated blood pressure, dyslipidemia, and type 2 diabetes mellitus for 
the South African population, based on current treatment levels (base case), versus with scale-up 
from currently-observed levels of treatment to 80% population access per the World Health 
Organization’s Package of Essential Non-communicable disease interventions (WHO PEN), or 
per the South Africa’s Primary Care 101 Guidelines (SA PC 101).20,21 95% confidence intervals 
in parentheses are calculated by re-running the model 10,000 times while repeatedly Monte 
Carlo sampling with replacement from the distributions of all input parameters to estimate 
uncertainty in the outcome metrics. Compare to main text Table 2. 
 
Outcome metric, 
mean (95% CI) 
Treatment condition 
Base case (current 
levels of treatment) 
WHO PEN 
guidelines 
implemented 
SA PC 101 
guidelines 
implemented 
Disability-adjusted life-years lost, per 1,000 population per year 
All simulated 
outcomes 
40.0 (29.5, 52.0) 31.7 (21.2, 43.7) 31.2 (20.7, 43.2) 
 
Atherosclerotic 
cardiovascular 
disease 
18.7 (15.8, 21.8) 12.8 (9.9, 15.9) 12.4 (9.5, 15.5) 
Congestive heart 
failure 
10.7 (7.3, 14.6) 9.7 (6.3, 13.6) 9.5 (6.1, 13.4) 
Renal failure/end-
stage renal disease 
9.2 (5.5, 13.5) 8.1 (4.4, 12.4) 8.1 (4.4, 12.4) 
Diabetic retinopathy 0.8 (0.5, 1.3) 0.6 (0.3, 1.1) 0.6 (0.3, 1.1) 
Diabetic neuropathy 0.6 (0.4, 0.8) 0.5 (0.3, 0.7) 0.5 (0.3, 0.7) 
Healthcare costs, $ per 1,000 population per year 
All simulated risk 
factors and outcomes 
607,820 (513,818, 
705,805) 
427,912 (206,236, 
667,277) 
384,623 (234,666, 
542,653) 
Hypertension 26,429 (26,326, 
26,533) 
22,069 (17,577, 
26,725) 
35,933 (29,785, 
41,568) 
Dyslipidemia 6,585 (6,308, 6,860) 10,754 (9,693, 
11,773) 
10,934 (9,855, 
12,048) 
Type 2 diabetes 
mellitus 
183,006 (170,185, 
195,023) 
99,787 (32,484, 
158,828) 
29,427 (7,277, 
51,516) 
Appendix Page 21 of 22 
Atherosclerotic 
cardiovascular 
disease 
248,108 (226,170, 
270,567) 
178,299 (134,417, 
217,148) 
176,691 (128,745, 
216,014) 
Congestive heart 
failure 
29,243 (21,778, 
37,251) 
22,952 (9,482, 
39,403) 
22,838 (9,482, 
40,200) 
Renal failure/end-
stage renal disease 
138,195 (87,520, 
192,544) 
113,870 (19,525, 
236,129) 
115,146 (11,409, 
236,129) 
Diabetic retinopathy 587 (371, 808) 401 (59, 854) 415 (119, 824) 
Diabetic neuropathy 2,096 (1,486, 2,752) 1,849 (579, 3,140) 1,849 (576, 3,140) 
Incremental cost-
effectiveness ratio 
(Change in $/change 
in DALYs), versus 
base case 
- -$21,668 (-$37,044 -
$4,640) 
-$25,347 (-$31,700, -
$18,528) 
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